Latest News

First Phosphate (NASDAQ:PHOS) is advancing an igneous phosphate project in Quebec aimed at supplying the lithium iron phosphate, or LFP, battery supply chain, Chief Executive Officer John Passalacqua said during a Virtual Investor Conferences presentation. Passalacqua described the company as a min

An earlier TFSA contribution can simplify your plan, even when the immediate tax saving is smaller than you expect.

Here's what the streaming landscape holds over the coming years.

Stocks like TD Bank and Fortis provide an anchor to a well-diversified portfolio for resilient long-term performance.

Learn why dividend cuts happen and how to spot warning signs, using BCE and TELUS to examine cash flow, debt, and payout sustainability.

Biomea Fusion (NASDAQ:BMEA) reported top-line results from a Phase Ib multiple ascending-dose study of BMF-650, an investigational oral small-molecule GLP-1 receptor agonist being developed for weight management. The company said the 28-day study showed weight reduction across active-treatment cohor

Selling stocks in a panic turns paper losses permanent. Discover how holding Aritzia stock through terrifying headlines delivered over 1,100% in long-term gains.

Why do the most credentialed people on Earth end up making the safest, most probable choices of their lives?

Brad Barrett, the co-founder of the ChooseFI website and the co-host of the ChooseFI podcast, advises on how to become financially independent.

This investing strategy can reduce risk while still delivering decent yield.

Hardly for the first time recently, the company earned a price target raise from an analyst.

Celestica’s AI exposure is supported by operating results, while cash investment and valuation make the buying decision more demanding.

Realty Income's stock price has substantially underperformed the S&P 500 over the last couple of months.

The S&P 500 just hit a record while the TSX sits 3.5% below its August peak. Here’s what home bias really costs Canadians, and 3 ETFs that can lower it now

Kura Oncology (NASDAQ:KURA) and its newly formed affiliate Caspian Therapeutics outlined plans to develop KO-7246, an oral menin inhibitor, for diabetes, citing preclinical data that the companies said showed beta-cell expansion, improved glucose control and sustained effects after treatment ended.

Aritzia’s upbeat outlook, strength in its e-commerce business, and boutique expansion indicate strong growth ahead.

Innovative Medicine drove 7.9% growth as revenue hit $25.4 billion.

Net income hit $60.2 million amid loan growth, but mortgage banking faced headwinds.

Net income surged 6% to $15.3 billion as investment banking and markets revenue accelerated.

Leadership transition underway as Domino's faces consumer spending pressures.

Record equities financing and $4.1T assets under supervision discussed.

Citigroup posts best Q3 revenue in a decade, net income surges 40% YoY.

Medical care ratio improved to 88.4% as AI initiatives reduce administrative friction.

CEO Morris warns traffic and units lag as retailer launches turnaround strategy.

Net income surged 43.5% as Sports School and Social segments both accelerated.